Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Recruiting 2Completed 1Active not recruiting 1

Sponsor Class

NIH 4INDUSTRY 2

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Neoplasms 79Lymphoma 62Breast Neoplasms 61Prostatic Neoplasms 60Multiple Myeloma 60Lung Neoplasms 55Neoplasm Metastasis 54Ovarian Neoplasms 47Leukemia, Myeloid, Acute 47Colorectal Neoplasms 41Hematologic Neoplasms 40Melanoma 39Carcinoma, Non-Small-Cell Lung 38Pancreatic Neoplasms 31Lymphoma, Non-Hodgkin 31Glioma 31Brain Neoplasms 30Urinary Bladder Neoplasms 28Myelodysplastic Syndromes 28Sarcoma 26Carcinoma, Renal Cell 26Glioblastoma 25Fallopian Tube Neoplasms 25Neuroblastoma 23Triple Negative Breast Neoplasms 22Leukemia, Lymphocytic, Chronic, B-Cell 22Burkitt Lymphoma 21Stomach Neoplasms 19Small Cell Lung Carcinoma 19Squamous Cell Carcinoma of Head and Neck 18

Interventions

Matrix-M 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
NIH × Infectious Mononucleosis × 1 year × Clear all
NCT00032513 2026-06-01

Genetic Studies of Chronic Active Epstein-Barr Disease

National Institutes of Health Clinical Center (CC)

Recruiting
300 enrolled
Lymphoid

Herpes Simplex, Infectious Mononucleosis, Lymphoproliferative Disorders, Virus Diseases, Epstein-Barr Virus Infections

NCT06908096 2026-05-18

Epstein-Barr Virus (EBV) gH/gL/gp42-Ferritin Nanoparticle Vaccine With or Without gp350-Ferritin in Healthy Adults With or Without EBV Infection

National Institutes of Health Clinical Center (CC)

Phase 1 Recruiting
750 enrolled

Infectious Mononucleosis, Epstein-Barr Virus Infections

NCT05683834 2026-04-22

Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
25 enrolled

Herpes Simplex, Infectious Mononucleosis, Epstein-Barr Virus Infections

NCT04645147 2025-07-17

Safety and Immunogenicity of an Epstein-Barr Virus (EBV) gp350-Ferritin Nanoparticle Vaccine in Healthy Adults With or Without EBV Infection

National Institutes of Health Clinical Center (CC)

Phase 1 Active not recruiting
83 enrolled

Infectious Mononucleosis, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡